Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 10Other hematologic neoplasm 10Lymphoid 10Breast 10Gastrointestinal 7Plasma cell 6Dermatologic 6Gynecologic 5Sarcoma 4Genitourinary 3Classical hematology 3CNS 2Other neoplasm 1Other 1Myeloid 1Head & Neck 1

Conditions

Brain Neoplasms 1050Glioblastoma 920Glioma 601Central Nervous System Neoplasms 436Astrocytoma 396Gliosarcoma 339Neuroblastoma 325Oligodendroglioma 255Neoplasms 181Medulloblastoma 165Breast Neoplasms 154Sarcoma 114Recurrence 108Ependymoma 105Neoplasm Metastasis 95Meningioma 91Melanoma 88Lymphoma 87Carcinoma, Non-Small-Cell Lung 87Lung Neoplasms 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Neurofibromatosis 1 78Wilms Tumor 75Osteosarcoma 69Head and Neck Neoplasms 69Ovarian Neoplasms 68Testicular Neoplasms 67Lymphoma, Non-Hodgkin 67Burkitt Lymphoma 66Familial ependymoma 63

Interventions

Vincristine 1Temozolomide 1Procarbazine 1Lomustine 1Irinotecan 1Genetic Therapy 1Filgrastim 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × CNS × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00005796 2015-03-25

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

Indiana University

Phase 1 Completed
10 enrolled
CNSSarcoma

Familial ependymoma, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡